Revanesse Contour (2x1ml)

Description

How does Revanesse Contour (2x1ml) work?

Revanesse Contour is the newest member of the Revanesse family of dermal fillers and is designed to provide ultra high viscosity and long lasting results.

It is a highly cross-linked hyaluronic acid gel which has been formulated for facial contouring and shaping.

It is said to be ideal for large volume treatments, mid face volumisation, chin and jaw augmentation and nose bride correction.

What’s in the box?

• 2x1ml syringes
• Hyaluronic Acid

What are the benefits of Revanesse Contour (2x1ml)?

Revanesse Contour can:

• Volumise skin
• Replace lost Hyaluronic Acid

Welcome, a reliable and convenient way for clinics, healthcare professionals and wholesalers to purchase farma chermical , and other medical devices from a trusted source at a competitive price.

the retail brand of CFL Health Solutions Ltd, an authorized wholesale distributor regulated by the Medicines and Health Regulatory Authority (MHRA) in the UK.

Providing on 3 European sites and with a global reach thanks to our superior logistics expertise, prides itself on its price, supply capabilities and service and as a result, we have a very loyal customer base and growing satisfied customers who are coming back to us repeatedly.

We supply all major brand names, including fentanil, insomnia, pain killers , pills form, and many other products. If you can not see a product you are looking for, please email us and we will source it for you. We also have our own products, and can represent quality tested products on behalf of manufacturers looking for retail distribution and / or launch via our platform.
Sign up today and once your account is verified, you can start enjoying the competitive prices our current customers enjoy. Please note that our injectables should only be administered by trained and / or accredited health professionals. If you have an interest in knowing the non-surgical procedures, we have our own training division led by experienced and skilled doctors who is living.

We recommend that you organize 4 or 5 weekly sessions followed by a “maintenance” session every 2 to 3 months, depending on your needs. You can resume your usual routine at the end of the treatment. The redness disappears in just a few hours.
The results are immediate and you will see an improvement in the first session. This is a treatment.
In the short term, your skin will appear smoother, brighter and firmer. In the longer term, rides and fine lines are reduced and your skin tightens.

drugs Originally synthesized by chemist Wayne E. Kenney, BAY is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotectiveeffects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
drugs has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and is currently in Phase II trials.But its development appears has stopped.
Originally synthesized by chemist Wayne E. Kenney, is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury.
Traumatic brain injury (TBI) is the most common cause of mortality and morbidity in adults under 40 years of age in industrialized countries. Worldwide the incidence is increasing, about 9.5 million people are hospitalized per year due to TBI, and the death rate is estimated to be more than one million people per year. Recently has been characterized as a structurally novel, selective and highly potent cannabinoid CB1/CB2 receptor agonist in vitro and in vivo with pronounced neuroprotective efficacy in a rat traumatic brain injury model, showing a therapeutic window of at least 5 h.